CXS Therapeutics

CXS Therapeutics is a French biotechnology company specializing in drug repurposing for incurable central nervous system (CNS) and rare diseases. Founded in 2023 by Guillaume Brachet, a pharmacist and researcher diagnosed with young-onset Parkinson's disease, the company utilizes a proprietary predictive bioinformatic platform to identify synergistic, patentable combinations of existing drugs. Its lead program, CXS003, is a low-dose combination of two antidiabetic drugs (metformin and glibenclamide) designed to provide neuroprotective effects in Parkinson's disease and amyotrophic lateral sclerosis (ALS). CXS Therapeutics operates as a platform company, spinning out clinical-stage assets into dedicated subsidiaries, such as SAPPIENS, which is advancing CXS003 toward Phase 2 clinical trials.